Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 18;58(4):555.
doi: 10.3390/medicina58040555.

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

Dured Dardari  1   2 , Claire Thomas  2 , Francois-Xavier Laborne  3 , Caroline Tourte  3 , Elodie Henry  3 , Megane Erblang  4 , Stéphanie Bourdon  5 , Alfred Penfornis  1   5 , Philippe Lopes  2
Affiliations

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

Dured Dardari et al. Medicina (Kaunas). .

Abstract

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.

Keywords: Charcot neuroarthropathy; HbA1c; diabetes; osteoprotegerin (OPG); receptor activator of nuclear factor-kappa B ligand (RANKL).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Ahmad S., Siddiqui Z., Rehman S., Yasir Khan M., Khan H., Khanum S., Alouffi S., Saeed M. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure. Curr. Vasc. Pharmacol. 2017;15:352–364. doi: 10.2174/1570161115666170327162639. - DOI - PubMed
    1. Akhter F., Khan M.S., Singh S., Ahmad S. An immunohistochemical analysis to validate the rationale behind the enhanced immunogenicity of D-ribosylated low density lipo-protein. PLoS ONE. 2014;9:e113144. doi: 10.1371/journal.pone.0113144. - DOI - PMC - PubMed
    1. Ahmad S., Uddin M., Habib S., Shahab U., Alam K., Ali A. Autoimmune response to AGE modified human DNA: Implications in type 1 diabetes mellitus. J. Clin. Transl. Endocrinol. 2014;1:66–72. doi: 10.1016/j.jcte.2014.05.002. - DOI - PMC - PubMed
    1. Siddiqui Z., Faisal M., Alatar A.R., Ahmad S. Prevalence of auto-antibodies against D-ribose-glycated-hemoglobin in diabetes mellitus. Glycobiology. 2019;29:409–418. doi: 10.1093/glycob/cwz012. - DOI - PubMed
    1. Nabi R., Alvi S.S., Shah M.S., Ahmad S., Faisal M., Alatar A.A., Khan M.S. A biochemical & biophysical study on in-vitro anti-glycating potential of iridin against d-Ribose modified BSA. Arch. Biochem. Biophys. 2020;686:108373. - PubMed